Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Multiple Myeloma 14Lymphoma, Non-Hodgkin 10Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Arthritis, Rheumatoid 7Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell 5Lymphoma 5Solid Tumors 4Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Melanoma 4Leukemia, Myeloid, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Colorectal Neoplasms 4Ovarian Neoplasms 3Lymphoma, Follicular 3Leukemia 3Hematologic Neoplasms 3Cytokine Release Syndrome 3Burkitt Lymphoma 3Urinary Bladder Neoplasms 2Respiratory Distress Syndrome 2Pancreatic Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Mantle-Cell 2Fallopian Tube Neoplasms 2Craniopharyngioma 2Carcinoma, Hepatocellular 2

Interventions

Doxorubicin 10Zidovudine 9Vincristine 7Bleomycin 7Nivolumab 6Liposomes 5Interferon alpha-2 5Etoposide 5tecogalan 4pembrolizumab 4liposomal doxorubicin 4Valganciclovir 4Specimen Handling 4Semaxinib 4Paclitaxel 4Nelfinavir 4Magnetic Resonance Spectroscopy 4pomalidomide 3Ritonavir 3Filgrastim 3Biopsy 3Bevacizumab 3technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 2sargramostim 2interferon alfa-n1 2Propranolol 2Indinavir 2Docetaxel 2Didanosine 2Daunorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Kaposi × tocilizumab × Clear all
NCT01441063 2020-10-27

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
8 enrolled 18 charts
LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Castleman Disease, Sarcoma, Kaposi

Data powered by HemOnc (CC BY 4.0) Colophon âš¡